- 36-month FIH data show sustained IOP reduction and drop-free outcomes
- Phase I/II trial interim results confirm strong efficacy and safety across larger population
- Phase III planning underway following FDA engagement
Breakthrough in Long-Acting Glaucoma Therapy
SpyGlass Pharma, a late-stage biopharmaceutical company developing long-acting drug delivery therapies for chronic eye diseases, today announced positive results from two clinical trials evaluating its lead product candidate, the Bimatoprost Drug Pad-Intraocular Lens (BIM-IOL) System, for the treatment of elevated intraocular pressure (IOP) in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).
The data, presented by Malik Kahook, M.D., co-founder and president of SpyGlass Pharma, at the Interventional Glaucoma Consortium (IGC) in Salt Lake City, Utah, included 36-month follow-up data from the first-in-human (FIH) trial and three-month interim results from the ongoing Phase I/II trial.
“The BIM-IOL System delivers sustained IOP reduction, drop-free outcomes, and strong visual performance over three years,” said Dr. Kahook. “Our Phase I/II trial shows similar outcomes in a broader patient population, reinforcing its potential to eliminate the adherence burden associated with daily eye drops.”
FIH Results at 36 Months
- 37% reduction in mean IOP across all dose groups (from 25.1 ± 2.5 mmHg at baseline to 15.9 ± 2.7 mmHg).
- 95% of patients remained off all topical IOP-lowering medications.
- 100% achieved 20/30 or better best-corrected distance visual acuity (BCDVA).
- No product-related adverse events (AEs) reported.
These findings demonstrate long-term, drop-free IOP control and excellent safety following implantation during routine cataract surgery.
Phase I/II Interim Results: Confirmed Efficacy and Safety
The Phase I/II trial is a multicenter, randomized, double-masked, controlled study evaluating two dose levels of the BIM-IOL System (78 mcg and 39 mcg) compared to a control group receiving a standard monofocal IOL plus twice-daily timolol drops.
At three months post-implantation:
- Mean IOP reduction: 37% (78 mcg) and 36% (39 mcg)—comparable to control (37%).
- 98% of patients (78 mcg) and 96% (39 mcg) were free of all topical IOP-lowering medications.
- Vision improvement: 20/40 or better BCDVA, with mean scores equivalent to ~20/20 vision (85–86 letters).
“The implantation procedure during cataract surgery is straightforward, and the three-month data show both sustained IOP reduction and strong visual outcomes,” said Jeffrey Kammer, M.D., associate professor of ophthalmology at Vanderbilt University Medical Center and Phase I/II trial investigator. “Long-term, sustained drug delivery options like this are exactly what our patients need.”
Safety Comparable to Routine Cataract Surgery
At the three-month mark:
- AE rates were similar across groups: 35.3% (78 mcg), 39.1% (39 mcg), and 33.3% (control).
- No serious ocular AEs were observed.
The safety profile supports the use of the BIM-IOL System during standard cataract surgery procedures.
About the BIM-IOL System
The SpyGlass BIM-IOL System integrates novel non-bioerodible drug pads containing bimatoprost, a prostaglandin analog first approved by the U.S. FDA in 2001 for topical use to reduce elevated IOP.
Designed to be implanted during routine cataract surgery, the system continuously delivers therapeutic levels of bimatoprost over multiple years, offering a potential drop-free alternative to conventional glaucoma therapy.
Next Steps: Advancing Toward Phase III
SpyGlass continues long-term patient follow-up in both the FIH and Phase I/II studies. The company plans to engage with the U.S. FDA to advance the program toward Phase III clinical trials, followed by a 505(b)(2) New Drug Application (NDA) submission and potential commercial approval.
About SpyGlass Pharma
SpyGlass Pharma is a late-stage biopharmaceutical company committed to transforming the treatment paradigm for chronic eye diseases through long-acting, sustained drug delivery of approved medicines. The company’s proprietary technology platforms aim to eliminate the adherence burden of daily eye drops while improving long-term disease control and visual outcomes.
